NCT01511497View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study Of PF-04427429 In Healthy Women Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
PainMigraine Disorders
Interventions
BIOLOGICAL

PF-04427429

Intravenous, single dose given over 1 hour with experimental dose. Subjects can receive one of four potential doses - 300, 1000, 1500 or 2000 mg.

OTHER

Normal saline

Intravenous, normal saline

Trial Locations (3)

33126

Pfizer Investigational Site, Miami

33134

Pfizer Investigational Site, Miami

75247

Pfizer Investigational Site, Dallas

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01511497 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study Of PF-04427429 In Healthy Women Volunteers | Biotech Hunter | Biotech Hunter